Patents and genome-wide DNA sequence analysis: is it safe to go into the human genome?
Patents and genome-wide DNA sequence analysis: is it safe to go into the human genome?
复制标题
DOI：
10.1111/jlme.12161
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Chandrasekharan S
中科院分区：
文献类型：
--
作者：
Cook-Deegan R;Chandrasekharan S
授予人类基因的专利是否以及在多大程度上给基因组学及其应用蒙上了不确定的阴影？单个基因或基因簇的专利拥有者是否会起诉那些对人类样本进行全基因组分析的人侵犯专利？这些相关的问题一直困扰着分子诊断公司和服务，影响着科学，临床和商业决策。全基因组分析方法的大量涌现能否在不担心专利侵权责任的情况下进行？全基因组测序（WGS）正在快速进行。学术中心已经在研究中进行了至少五年的全基因组和外显子组测序（WES），并且具有全国影响力的学术临床实验室已经为临床应用进行了几乎同样长的测序。几年来，公司也一直在提供WGS和WES作为临床服务。据我们所知，目前还没有人因侵犯“基因专利”而被起诉。
Whether, and to what degree, do patents granted on human genes cast a shadow of uncertainty over genomics and its applications? Will owners of patents on individual genes or clusters of genes sue those performing whole-genome analyses on human samples for patent infringement? These are related questions that have haunted molecular diagnostics companies and services, coloring scientific, clinical, and business decisions. Can the profusion of whole-genome analysis methods proceed without fear of patent infringement liability?Whole-genome sequencing (WGS) is proceeding apace. Academic centers have been performing whole-genome and -exome sequencing (WES) in research for at least five years, and academic clinical laboratories with national reach have been doing sequencing for clinical applications for almost as long. Companies have also been offering WGS and WES as a clinical service for a few years now. So far as we know, no one has been sued for infringement of “gene patents” for performing WGS.
DOI：
10.1038/gim.2013.73
发表时间：
2013-07
期刊：
Genetics in medicine : official journal of the American College of Medical Genetics
影响因子：
--
作者：
通讯作者：
--
影响因子：
56.9
作者：
KILEY, TD
通讯作者：
KILEY, TD
影响因子：
158.5
作者：
HEALY, B
通讯作者：
HEALY, B